| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2013 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Calumet Specialty Products Partners, LP | 11 | Q2 2024 | 31.5% |
| Alphabet Inc-Cl C | 11 | Q2 2024 | 8.2% |
| DocGo, Inc. | 11 | Q2 2024 | 5.8% |
| Ligand Pharmaceuticals Incorporated | 11 | Q2 2024 | 4.3% |
| Pfizer Inc. | 11 | Q2 2024 | 3.2% |
| JPMorgan Chase & Co. | 11 | Q2 2024 | 1.7% |
| Avadel Pharmaceuticals plc | 11 | Q2 2024 | 2.0% |
| Viking Therapeutics, Inc. | 11 | Q2 2024 | 2.9% |
| Vertex Pharmaceuticals, Inc. | 11 | Q2 2024 | 2.1% |
| AllianceBernstein Holdings PL Unit LTD | 11 | Q2 2024 | 0.9% |
View Knott David M Jr's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| MIDWEST HOLDING INC.Sold out | December 22, 2023 | 0 | 0.0% |
| Calumet Specialty Products Partners, L.P. | November 08, 2021 | 4,292,200 | 5.4% |
View Knott David M Jr's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-29 |
| 13F-HR | 2024-08-12 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 4 | 2023-12-22 |
| SC 13D/A | 2023-12-22 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
View Knott David M Jr's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.